These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27815374)

  • 1. Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.
    Kim JT; Fonarow GC; Smith EE; Reeves MJ; Navalkele DD; Grotta JC; Grau-Sepulveda MV; Hernandez AF; Peterson ED; Schwamm LH; Saver JL
    Circulation; 2017 Jan; 135(2):128-139. PubMed ID: 27815374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
    Saver JL; Fonarow GC; Smith EE; Reeves MJ; Grau-Sepulveda MV; Pan W; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2013 Jun; 309(23):2480-8. PubMed ID: 23780461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
    Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
    JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry.
    Dorado L; Ahmed N; Thomalla G; Lozano M; Malojcic B; Wani M; Millán M; Tomek A; Dávalos A
    Stroke; 2017 Mar; 48(3):720-725. PubMed ID: 28174326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.
    Cronin CA; Langenberg P; Dutta TM; Kittner SJ
    Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
    Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
    Man S; Xian Y; Holmes DN; Matsouaka RA; Saver JL; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC
    JAMA; 2020 Jun; 323(21):2170-2184. PubMed ID: 32484532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.
    Messé SR; Fonarow GC; Smith EE; Kaltenbach L; Olson DM; Kasner SE; Schwamm LH
    Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):321-6. PubMed ID: 22550132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
    Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
    Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke.
    Kamal N; Sheng S; Xian Y; Matsouaka R; Hill MD; Bhatt DL; Saver JL; Reeves MJ; Fonarow GC; Schwamm LH; Smith EE
    Stroke; 2017 Apr; 48(4):946-954. PubMed ID: 28228574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.
    Ido MS; Okosun IS; Bayakly R; Clarkson L; Lugtu J; Floyd S; Krompf K; Frankel M
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):866-71. PubMed ID: 26853143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of endovascular treatment after 6 hours of symptom onset in patients with anterior circulation ischemic stroke: a matched case control study.
    Qureshi AI; Miley JT; Chaudhry SA; Semaan E; Rodriguez GJ; Suri MF; Adams HP
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1076-81. PubMed ID: 23099041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke.
    Xian Y; Smith EE; Zhao X; Peterson ED; Olson DM; Hernandez AF; Bhatt DL; Saver JL; Schwamm LH; Fonarow GC
    Stroke; 2014 May; 45(5):1387-95. PubMed ID: 24713527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study.
    Ahmed N; Kellert L; Lees KR; Mikulik R; Tatlisumak T; Toni D;
    JAMA Neurol; 2013 Jul; 70(7):837-44. PubMed ID: 23689267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of recanalization after microbubble-enhanced intravenous thrombolysis in basilar artery occlusion.
    Pagola J; Ribo M; Alvarez-Sabín J; Lange M; Rubiera M; Molina CA
    Stroke; 2007 Nov; 38(11):2931-4. PubMed ID: 17901389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.